BELLUS Health reports results for the fourth quart... (e reporting currency differs from the me...)

BELLUS Health reports results for the fourth quarter of 2008

Date:2/26/2009

e reporting currency differs from the measurement currency or there is a change in the reporting currency". In accordance with EIC-130, assets and liabilities as of June 30, 2007 were translated in US dollars using the exchange rate in effect on that date; revenues, expenses and cash flows were translated at the average rate in effect during the six-month period ended June 30, 2007 and equity transactions were translated at historical rates. Any exchange differences resulting from the translation were included in accumulated other comprehensive income presented in shareholders' equity. Financial statements presented after June 30, 2007, are measured and presented in US dollars.

Forward-looking statements

Certain statements included in this Management's Discussion and Analysis may constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995 and Canadian securities legislation and regulations, and are subject to important risks, uncertainties and assumptions. This forward-looking information includes among others, the ability to obtain financing immediately in current markets, information with respect to the Company's objectives and the strategies to achieve these objectives, as well as information with respect to the Company's beliefs, plans, expectations, anticipations, estimates and intentions. Forward-looking statements generally can be identified by the use of conditional or forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "plan", "foresee", "believe" or "continue" or the negatives of these terms or variations of them or similar terminology. Refer to the Company's filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission, for a discussion of the various factors that may affect the Company's future results. Such risks include but are not limited to: the impact of general economic
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.

Post Your Comments:

(Date:5/22/2013)... 22, 2013 CoCENTRIX, a leading ... Health and Human Services and community providers, announced ... (ADMH) selected the CoCENTRIX Coordinated Care Platform ... the Health Records and coordinate care within and ... , CoCENTRIX is transitioning the hospitals' official records ...

(Date:5/22/2013)... 22, 2013 LDM Global ( http://www.ldmglobal.com ... services for law firms, corporations and government agencies announces ... cloud-based e-discovery software company, to deliver defensible ESI collections ... partnership, Cumulus Data and LDM Global hosted a VIP ... Tuesday, May 21st. This event was in conjunction ...

(Date:5/22/2013)... May 22, 2013 BroadConnect Telecom, ... and IT security solutions in North America announced ... of its newest BroadConnect hosted security solutions. Available ... hybrid combination, BroadConnect’s new Security as a Service ... the Internet connection of their choice, while optimizing ...

(Date:5/22/2013)... Poor adherence to appropriate medication therapy has ... and death (some 125,000 deaths in the U.S. every ... costs. It’s been estimated that between 33% and 69% ... medication adherence — a reality that costs the American ... dire is the degree of medication non-adherence — and ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Mari’s Skin Care, ... has become the first in the state of Texas to ... Meta Therapy- Medical and Esthetic Tissue Activation, also known as ... over four years in Europe, but has just recently made ... improves the skin from inside out by building collagen and ...

Breaking Medicine News(10 mins):Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2 Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3 Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 2 Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 3 Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2 Health News:Mari's to Offer New Treatment from Europe 2

[0] The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals [0] LDM Global Enhances Forensic Data Collection Services with eCloudCollect [0] BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance [0] Mari's to Offer New Treatment from Europe

... to a new report by the UNH scientist, the beginning ... The effect, which is a result of global warming, has ... a ripple effect in all the happenings takes place in ... March 20th marking the vernal equinox and the official start ...

... a simple and natural remedy for reducing the intensity ... // by just eating more fruits and vegetables. They ... antioxidants, are capable of accelerating and worsening an attack. ... to a diet low in antioxidants and their asthma ...

... of seagrass beds around the world has resulted ... and sediment stabilizers affecting the shallow-water ecosystems // ... resources and marine science, University of New Hampshire. ... deeply affected even the commercially valuable valuable shellfish ...

... have discovered how to measure the absorption of multi-walled ... nanotubes were discovered in 1991, and have a great ... storage in fuel cells. But despite their promise, a ... carbon nanotubes will impact the living environment. This discovery ...

... release on the 28th regarding a study on stethoscope accuracy ... that physicians with more experience // are better able to ... heart disease. The researchers felt that with a greater experience ... pathologic heart disorders., ,Publishing their findings in the March ...

... The New York State Department of Health has confirmed coliform ... by North Country Spring Water//, Ltd. For this reason ... recalling all of its bottled water products. Coliform bacteria ... presence of coliform bacteria in bottled water is a violation ...

Cached Medicine News:Health News:‘Natural Spring’ Starts A Week Ahead Now Than Before: UNH Scienti 2 Health News:‘Natural Spring’ Starts A Week Ahead Now Than Before: UNH Scienti 3 Health News:Global Seagrass Decline Affects Shallow-water Ecosystems 2 Health News:Global Seagrass Decline Affects Shallow-water Ecosystems 3 Health News:Absorption Of Carbon Nanotube Measured In Worms Revolutionize Cancer Research 2 Health News:Experienced Physicians Diagnose Heart Disease’s Earlie 2

‘Natural Spring’ Starts A Week Ahead Now Than Before: UNH Scienti Abundant Asthma Benefits Found In Fruits and Vegetables Global Seagrass Decline Affects Shallow-water Ecosystems Absorption Of Carbon Nanotube Measured In Worms Revolutionize Cancer Research Experienced Physicians Diagnose Heart Disease’s Earlie Bottled Water Contains Coliform Bacteria and Diatoms

(Date:5/22/2013)... N.Y. , May 22, 2013 MGT Capital ... Company will present at the Second Annual Marcum LLP ... New York City at the Grand ... and Chief Executive Officer, will update investors and answer ... The Company,s presentation is scheduled to begin at ...

(Date:5/22/2013)... MAPLE GROVE, Minn. , May 22, ... today announced the successful completion of its ... (extended-release topiramate), an internally developed program for ... the company,s proprietary formulation technology. USL255 is ... and reduce fluctuations in topiramate blood levels ...

(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...

Breaking Medicine Technology:MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6

[0] MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference [0] Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures [0] Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance

... designed for more uniform drug ... ... Boston,Scientific Corporation (NYSE: BSX ) today announced comprehensive data ... historically controlled trials, which evaluate,the TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent System in ...

... with Kogenate FS Reduces the,Risk of Joint Damage ... Damage, BERKELEY, Calif., Oct. 10 Bayer ... Drug Administration (FDA) has,approved routine prophylaxis with Kogenate(R) ... bleeding episodes and the risk of,joint damage in ...

Cached Medicine Technology:Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2 Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3 Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4 Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5 Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6 FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2 FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3 FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4 FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....

Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....

Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....

Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....

Medicine Products:

Full Handle Laseredge Implant Blade Knife, 4.0 mm straight Full Handle Laseredge Crescent Blade Knife, straight Full Handle Laseredge Stab Blade Knife, 45 blade Full Handle Laseredge Stab Blade Knife, 15 blade